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        Introduction 
  The dystrophin  –  glycoprotein complex (DGC) is composed of 
integral and peripheral membrane proteins that span the plasma 
membrane and connect the extracellular matrix with the intra-
cellular actin cytoskeleton (  Campbell and Kahl, 1989  ;   Ervasti 
et al., 1990, 1991  ;   Yoshida and Ozawa, 1990  ;   Ervasti and 
Campbell, 1991, 1993  ). In skeletal muscle, the DGC provides me-
chanical stability to the sarcolemma during contraction (  Petrof 
et al., 1993  ). Mutations in the dystrophin gene are responsible 
for X-linked Duchenne muscular dystrophy (DMD), which is 
characterized by progressive wasting of skeletal muscles even-
tually resulting in cardiac and respiratory failure (for review see 
  Durbeej and Campbell, 2002  ). In DMD patients, loss of dystro-
phin results in the absence of the entire DGC complex, leading 
to severe membrane damage and muscle degeneration (for re-
view see   Durbeej and Campbell, 2002  ).   mdx   mice, which are an 
established model for DMD, possess a genetic mutation in exon 
23 of the murine dystrophin gene, resulting in loss of dystrophin 
protein. As a result, the entire DGC is also absent from the sar-
colemma, likely because of rapid protein degradation in the 
absence of a fully assembled complex. Muscles from   mdx   mice 
are pathologically similar to DMD patients and display marked 
membrane disruption as a result of sarcolemmal instability. Akt 
signaling is hyperactivated in muscles from DMD patients and 
  mdx   mice (  Peter and Crosbie, 2006  ), suggesting that the DGC 
may also play a role in cellular signaling in addition to its role 
in mechanical stability of the sarcolemma (  Judge et al., 2006  ). 
  The transmembrane proteins of the DGC serve as impor-
tant anchorages for the peripheral membrane DGC components. 
These integral membrane proteins include sarcospan (SSPN), 
the sarcoglycans (SGs;    -,    -,     -, and     -SG), and    -dystrogly-
can (DG; for review see   Michele and Campbell, 2003  ). The SGs 
and     -DG are single-pass transmembrane glycoproteins. Dys-
trophin, an actin-binding protein, is localized adjacent to the 
sarcolemma by attachment to the intracellular N terminus of 
    -DG (for review see   Michele and Campbell, 2003  ). On the extra-
cellular face of the membrane,     -DG interacts with    -DG  to 
form a receptor for ligands in the extracellular matrix (  Ervasti 
and Campbell, 1993  ). The SGs form a tight subcomplex with 
SSPN (  Crosbie et al., 1999  ;   Miller et al., 2007  ). Together, the 
SG  –  SSPN subcomplex functions to anchor     -DG attachment to 
the sarcolemma ( Holt and Campbell, 1998 ). As a whole, the DGC 
provides a physical linkage across the sarcolemma between the 
extracellular matrix and the intracellular actin cytoskeleton 
protecting the membrane from contraction-induced damage (for 
review see   Barresi and Campbell, 2006  ). 
M
utations in the dystrophin gene cause Duchenne 
muscular dystrophy and result in the loss of dys-
trophin and the entire dystrophin  –  glycoprotein 
complex (DGC) from the sarcolemma. We show that 
sarcospan (SSPN), a unique tetraspanin-like component of 
the DGC, ameliorates muscular dystrophy in dystrophin-
deﬁ  cient   mdx   mice. SSPN stabilizes the sarcolemma by 
increasing levels of the utrophin  –  glycoprotein complex 
(UGC) at the extrasynaptic membrane to compensate for 
the loss of dystrophin. Utrophin is normally restricted to 
the neuromuscular junction, where it replaces dystrophin 
to form a functionally analogous complex. SSPN directly 
interacts with the UGC and functions to stabilize utrophin 
protein without increasing utrophin transcription. These 
ﬁ  ndings reveal the importance of protein stability in the 
prevention of muscular dystrophy and may impact the 
future design of therapeutics for muscular dystrophies.
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dystrophin-defi  cient muscle might anchor the transmembrane 
components of the DGC within the sarcolemma. To test this 
hypothesis, we engineered transgenic mice to overexpress SSPN 
on the dystrophin-defi  cient   mdx   background (SSPN-Tg:  mdx ). 
The   mdx   phenotype is inherited as an X-linked recessive trait, 
which stems from a premature stop codon in the dystrophin gene, 
leading to complete absence of the dystrophin protein. The DGC 
is absent from the sarcolemma of   mdx   muscle likely because of 
premature degradation of the protein components in the absence 
of a fully assembled complex (  Ohlendieck and Campbell, 1991  ). 
For these experiments, we chose to use low (two- to threefold) 
SSPN-transgenic (SSPN-Tg) mice, lines 31.6 and 29.1, which dis-
played normal muscle morphology (  Peter et al., 2007  ). SSPN-
Tg mice were engineered to carry the human SSPN (hSSPN) 
gene under control of the human skeletal muscle    -actin  pro-
moter, which limited SSPN protein expression to skeletal mus-
cles (  Peter et al., 2007  ). Although human and mouse SSPN 
proteins are   >  90% identical at the amino acid level, antibodies 
specifi  c to human and mouse SSPN permitted us to distinguish 
between exogenous (human) and endogenous (mouse) SSPN. 
SSPN-Tg males were crossed with   mdx   females to generate 
dystrophin-defi  cient mice carrying the SSPN Tg (SSPN-Tg:  mdx ). 
 We  fi rst investigated whether SSPN overexpression af-
fected membrane association of DGC components in dystrophin-
defi  cient muscle. Indirect immunofl  uorescence was performed 
on transverse cryosections of SSPN-Tg:  mdx   quadriceps muscle 
to determine the subcellular localization of the other DGC com-
ponents. In addition to the core components of the DGC, we 
also analyzed the localization of utrophin, a protein closely re-
lated to dystrophin. At the postsynaptic region of the neuromus-
cular junction in wild-type and   mdx   muscle, utrophin replaces 
dystrophin to form an otherwise identical utrophin  –  glyco-
protein complex (UGC;   Matsumura et al., 1992  ). Analysis of 
wild-type non-Tg and SSPN-Tg muscle served as positive con-
trols, and   mdx   muscle was used as a negative control. As shown 
in   Fig. 1  , DGC expression was robust in positive controls (wild-
type non-Tg and SSPN-Tg) but was not detected in negative 
control samples (  mdx   and SSPN-Tg:  mdx  ). As expected, staining 
for exogenous SSPN (hSSPN) was only detected in SSPN-Tg 
muscle, and utrophin expression was restricted to the neuro-
muscular junction in wild-type non-Tg and SSPN-Tg muscles 
(  Fig. 1  ). In agreement with previous results (  Matsumura et al., 
1992 ), we found that utrophin expression was slightly up-regulated 
in   mdx   muscle at the extrasynaptic sarcolemma. Surprisingly, 
we found that overexpression of SSPN in   mdx   muscle  broad-
ened the localization of utrophin protein so that it was no 
longer restricted to the neuromuscular junction but was present 
throughout the sarcolemma (  Fig. 1  ).   Grady et al. (2000)   have 
demonstrated that expression and localization of the UGC is 
important for proper synaptic formation and clustering of ace-
tylcholine receptors at the postsynaptic membrane. Introduction 
of utrophin in dystrophin-defi  cient muscle broadens localiza-
tion of the UGC to the extrasynaptic sarcolemma, where it ame-
liorates muscular dystrophy (  Tinsley et al., 1996, 1998  ). The 
observation that utrophin is localized to the extrasynaptic sarco-
lemma in SSPN-Tg:  mdx   muscle raises the possibility that utrophin 
displays elevated protein levels leading to the observed increased 
  It is well established that stable interactions among the 
integral membrane proteins are critical for DGC function and 
prevention of muscular dystrophy (for review see   Durbeej and 
Campbell, 2002  ). Despite their importance, the factors that 
determine the structural integrity of the DGC are not well under-
stood. The observation that SSPN possesses some sequence 
homology to the tetraspanin superfamily of proteins raises the 
possibility that SSPN may serve an important role in mediating 
and stabilizing protein interactions within the DGC (  Crosbie 
et al., 1997, 1998, 1999  ). The tetraspanins each possess four trans-
membrane domains and function to cluster and organize trans-
membrane protein complexes, thereby controlling a wide range 
of cellular functions (for reviews see   Hemler, 2003  ;   Levy and 
Shoham, 2005  ). Using a site-directed mutagenesis approach, we 
have demonstrated that SSPN exhibits the structural character-
istics that defi  ne the tetraspanin superfamily of proteins (  Miller 
et al., 2007  ). 
  As a fi  rst test of SSPN function, we generated SSPN trans-
genic (SSPN transgene [Tg]) mice with moderate (10-fold) levels 
of SSPN protein overexpression in skeletal muscle (  Peter et al., 
2007  ). Forced elevation of SSPN caused a concomitant increase 
in DGC protein expression but did not disrupt localization of the 
complex to the sarcolemma. We found that overexpression of 
exogenous SSPN dramatically reduced endogenous SSPN to 
levels that were barely detectable, suggesting that SSPN expres-
sion is tightly regulated. 10-fold elevation of SSPN disrupted 
normal interactions within the SG – SSPN subcomplex, which, in 
turn, weakened     -DG attachment to the sarcolemma (  Peter et al., 
2007  ). As a result, assembly of the extracellular matrix was dis-
rupted, giving rise to severe congenital muscular dystrophy in 
mice with moderate levels of SSPN overexpression (  Peter et al., 
2007  ). Furthermore, membrane instability was not detected in 
10-fold SSPN-Tg mice, demonstrating that pathogenetic mech-
anisms resulting from SSPN overexpression are distinct from 
dystrophin defi  ciency. Despite our exhaustive efforts, we were 
never able to isolate free, unassociated SSPN in 10-fold SSPN-
Tg muscle, which strongly supports our conclusion that SSPN  ’  s 
toxicity is directly related to its association with other molecules 
within the sarcolemma. 
  SSPN-Tg mice with low levels of SSPN overexpression 
(two- to threefold) were also characterized (  Peter et al., 2007  ). 
In contrast to SSPN-Tg mice with 10-fold levels of overexpres-
sion, SSPN-Tg mice with low levels of SSPN overexpression 
did not exhibit detectable signs of muscle pathology. DGC lev-
els were mildly up-regulated in these mice, but interactions with 
the extracellular matrix were not adversely affected. Endoge-
nous SSPN was not affected by this low level of exogenous 
SSPN expression. Collectively, these fi  ndings lead us to con-
clude that SSPN levels control DGC structure and function. 
Furthermore, this work leads to the hypothesis that SSPN may 
function to orchestrate assembly and stability of the DGC. 
  Results and discussion 
  Our previous work has shown that SSPN functions as a tetra-
spanin to coordinate protein interactions within the DGC (  Peter 
et al., 2007  ), which led us to rationalize that SSPN expression in 421 SARCOSPAN REDUCES DYSTROPHIC PATHOLOGY   • Peter et al. 
  Figure 1.       SSPN stabilizes the UGC at the sarcolemma.   Transverse cryosections of quadriceps muscle from non-Tg (wild type), SSPN-Tg (wild type),   mdx  , 
and SSPN-Tg:  mdx   mice were stained with the antibodies to dystrophin (Dys), utrophin (Utrn), DGs (    - and     -DG), mouse SSPN (mSSPN), transgenic hSSPN, 
and SGs (    - and     -SG). Protein staining was visualized by indirect immunoﬂ  uorescence. Bar, 100   μ  m.     JCB • VOLUME 183 • NUMBER 3 • 2008  422
tive to   mdx   controls (  Fig. 2 A  ). DG and SG protein expression 
in SSPN-Tg:  mdx   muscle was identical to age-matched non-Tg 
(wild type) muscle (  Fig. 2 A   and not depicted). As expected, 
dystrophin protein was not detected in samples from either   mdx  
or SSPN-Tg:  mdx   mice. Utrophin protein levels were elevated in 
SSPN-Tg:  mdx   muscle relative to   mdx   muscle (  Fig. 2 A  ). To in-
vestigate whether SSPN increased utrophin expression by en-
hancing transcription, we performed quantitative RT-PCR analysis. 
Utrophin mRNA levels were similar in SSPN-Tg:  mdx   and   mdx  
muscle (  Fig. 2 B  ). This fi  nding demonstrates that utrophin up-
regulation by SSPN does not involve transcriptional regulation. 
Furthermore, these data suggest that SSPN maintains utrophin 
protein at the sarcolemma by providing a tetraspanin scaffold, 
which stabilizes and promotes protein interactions. 
  We established that SSPN is a core component of the DGC 
using rigorous biochemical methods (  Crosbie et al., 1997, 1998 ). 
sarcolemmal localization and possible functional replacement of 
the DGC. We also found that SSPN overexpression in   mdx   mus-
cle increased    -/   -DG as well as    -/   -SG levels at the sar-
colemma (  Fig. 1  ). These data suggest that SSPN has restored 
expression of a complete UGC at the sarcolemma in   mdx   mus-
cle, where it may functionally compensate for the loss of dystro-
phin and its associated proteins. 
  To determine how SSPN expression affects UGC protein 
levels, skeletal muscle lysates from 6-wk-old   mdx   and SSPN-
Tg:  mdx   mice were analyzed by immunoblotting with antibodies 
to each of the UGC components. To confi  rm expression of the 
Tg, immunoblots were probed with antibodies specifi  c to hSSPN. 
Exogenous SSPN was abundant in SSPN-Tg:  mdx   muscle sam-
ples, demonstrating that stable SSPN protein was produced from 
the Tg (  Fig. 2 A  ). Levels of    -  and     -DG as well as    -,    -,  and 
    -SG were dramatically increased in SSPN-Tg:  mdx   mice  rela-
  Figure 2.       SSPN regulates UGC levels by interacting directly with this complex.   (A) Skeletal muscle from   mdx   and SSPN-Tg:  mdx   tissue was solubilized in 
modiﬁ  ed radioimmunoprecipitation assay buffer, and 60-  μ  g protein samples were resolved by SDS-PAGE and immunoblotted using antibodies against 
dystrophin (Dys), utrophin (Utrn), DGs (    - and     -DG), exogenous SSPN (hSSPN), and SGs (    -,     -, and     -SG). As expected, exogenous hSSPN was only 
detected in SSPN-Tg:  mdx   muscle. Expression levels of DGs and SGs were dramatically elevated in SSPN-Tg:  mdx   muscle samples. Utrophin, a homologue 
of dystrophin, is up-regulated in SSPN-Tg:  mdx   tissue. Equal loading of   mdx   and SSPN-Tg:  mdx   lysates was conﬁ  rmed by Coomassie blue (CB) staining. 
Molecular masses of individual proteins are indicated in parentheses. (B) Quantitative RT-PCR analysis was used to determine the level of utrophin mRNA 
in both SSPN-Tg:  mdx   and   mdx   tissue. Data are normalized to GAPDH controls and are represented relative to control values (100%). Utrophin mRNA 
levels were not statistically different (standard   t   test; P = 0.258) between SSPN-Tg:  mdx   and   mdx   controls, suggesting that SSPN-Tg expression did not 
affect utrophin transcription. Values represent mean   ±   SEM (error bars). (C) SSPN is a core component of the UGC in SSPN-Tg:  mdx   mice. Puriﬁ  ed UGC 
proteins were separated by ultracentrifugation through 5  –  30% sucrose gradients. Fraction 1 represents the lightest region of the gradient. Fractions were 
analyzed by immunoblotting with antibodies to utrophin (Utrn), DGs (    - and     -DG), SGs (    -, and     -SG), and exogenous SSPN (hSSPN) as indicated. SSPN 
and utrophin are enriched in fraction 4, demonstrating that SSPN is a core component of the UGC. The molecular mass of each component is identical to 
that indicated in A.     423 SARCOSPAN REDUCES DYSTROPHIC PATHOLOGY   • Peter et al. 
  To investigate the functional consequences of increased 
UGC levels in dystrophin-defi  cient muscle, we examined SSPN-
Tg:  mdx   muscle for dystrophic pathology.   mdx   pathology is char-
acterized by progressive muscle degeneration, compensatory 
hypertrophy, and necrosis of damaged muscle fi  bers. Histologi-
cal analysis was performed by staining transverse cryosections 
of quadriceps muscle with hematoxylin and eosin (H  &  E). 
Images of whole quadriceps muscle taken from   mdx   mice revealed 
numerous patches of necrosis, which were not present in SSPN-
Tg:  mdx   muscle (  Fig. 3 A  ). Central nucleation, a marker of myo-
fi  ber regeneration, was quantitated by analyzing H  &  E-stained 
quadriceps muscle at higher magnifi  cation (  Fig. 3 B  ).   mdx   mus-
cles at 6 wk of age display elevated levels (60%) of regenerated 
myofi  bers with central nuclei (  Fig. 4 A  ). We found a dramatic 
(40%) reduction in central nucleation in muscle from SSPN-
Tg:  mdx   mice (  Fig. 4 A  ). Although the level of centrally nucle-
ated fi  bers in SSPN-Tg:  mdx   mice remained slightly elevated 
compared with non-Tg controls, this is likely explained by fi  ber 
to fi  ber variation in promoter activation (unpublished data). 
In normal skeletal muscle, SSPN is enriched at the postsynaptic 
region of the neuromuscular junction in a utrophin-dependent 
manner (  Crosbie et al., 1999  ). Our fi  ndings that SSPN expres-
sion alters utrophin localization and, conversely, that SSPN 
enrichment at the neuromuscular junction is dependent on utro-
phin suggest that SSPN functions to regulate utrophin through 
direct association with the UGC. To biochemically determine 
whether SSPN is a core component of the UGC, we isolated this 
complex from skeletal muscle of SSPN-Tg:  mdx   mice using lec-
tin affi  nity chromatography followed by ultracentrifugation on 
5  –  30% sucrose gradients. Only proteins that are tightly associ-
ated will be maintained as a complex and migrate together dur-
ing ultracentrifugation (  Crosbie et al., 1997, 1998  ). Fractions 
were collected and analyzed by immunoblotting with antibodies 
to components of the UGC. We found that SSPN protein is 
highly enriched in fraction 4, which contains utrophin and utro-
phin-associated proteins (  Fig. 2 C  ). We conclude that SSPN 
regulates utrophin levels in a mechanism that involves direct as-
sociation of SSPN with the UGC. 
  Figure 3.       SSPN-Tg:  mdx   mice display near normal muscle pathology.   (A) Transverse cryosections of whole quadriceps muscle from age-matched   mdx   
and SSPN-Tg:  mdx   mice were stained with H  &  E to visualize muscle pathology. Many necrotic patches are visible in   mdx   quadriceps. Necrotic ﬁ  bers were 
never observed in SSPN-Tg:  mdx   quadriceps. Boxed regions indicated on H  &  E staining of quadriceps muscle from   mdx   and SSPN-Tg:  mdx   mice are shown 
at higher magniﬁ  cations in B. Note the presence of numerous myoﬁ  bers with central nucleation as well as the variation in ﬁ  ber size evident in   mdx   tissue. 
Muscle from SSPN-Tg:  mdx   muscle displays reduced central nucleation and improvements in ﬁ  ber size variation. Bar, 100   μ  m.     JCB • VOLUME 183 • NUMBER 3 • 2008  424
fl  uorescent Evans blue dye that binds albumin in blood serum 
(  Straub et al., 1997  ).   mdx   mice displayed severe sarcolemmal 
fragility marked by Evans blue dye accumulation in numerous 
muscle fi  bers (  Fig. 4 B  ). In contrast, we never observed Evans 
blue – positive  fi  bers in SSPN-Tg:  mdx   tissue (  Fig. 4 B  ). 
  In this study, we provide biochemical evidence that SSPN 
ameliorates dystrophic pathology in   mdx   mice by stabilizing 
the UGC at the sarcolemma through direct interaction with this 
complex. We demonstrate that SSPN causes redistribution of the 
UGC to the extrasynaptic sarcolemma, where it functionally re-
places the DGC. The primary defect in dystrophin-defi  cient mice 
is the loss of sarcolemma integrity, and we demonstrate that 
SSPN provides stability to the sarcolemma. These data suggest 
that the actin-UGC  –  extracellular matrix connection is fully and 
functionally restored. Future studies will be performed to deter-
mine whether SSPN overexpression improves muscle strength 
in   mdx   mice. 
    Tinsley et al. (1996, 1998)   have shown that increased ex-
pression of utrophin in   mdx   mice rescues muscular dystrophy 
by stabilizing the UGC at the sarcolemma in a dose-dependent 
manner. Complete reduction of   mdx   pathology to normal wild-
type levels (as determined by central nucleation and muscle strength 
measurements) occurred when utrophin was overexpressed at 
twice the levels of   mdx   mice (note that endogenous utrophin 
levels are already up-regulated in   mdx   muscle compared with 
wild-type controls). Their data nicely show that pathology was 
directly correlated with the level of utrophin overexpression. 
Lower levels of utrophin expression reduced the pathology, but 
not completely back to normal levels. Based on these fi  ndings, 
we speculate that increasing the level of SSPN overexpression 
would have an even greater impact on improving   mdx   pathology. 
  Overexpression of DGC proteins, signaling molecules, and 
compensatory molecules can improve the pathology of muscle 
fi  bers in the   mdx   mouse. Utrophin, dystrophin, integrin, neuronal 
nitric oxide synthase, and cytotoxic T cell   N -acetylgalactosamine 
transferase have been shown to improve muscular dystrophy. 
Most of these efforts have been focused on the use of dystrophin 
and utrophin to restore normal muscle function in   mdx   mice. 
Elegant work from Chamberlain  ’  s group has established that 
full-length (  DelloRusso et al., 2002  ) and internally truncated 
forms of dystrophin are highly effective at ameliorating   mdx  
pathology in addition to increasing muscle strength (for review 
see   Odom et al., 2007  ). SSPN is unique and offers numerous 
advantages over current therapeutic strategies. The SSPN cDNA 
is under 1 kb, which is well within the range for easy packaging 
into adeno-associated viral vectors for delivery, circumventing the 
necessity to generate recombinant forms of SSPN. Because SSPN 
is expressed in a variety of nonmuscle tissues, even in dystro-
phin defi  ciency, increasing the expression of SSPN in skeletal 
muscle should not pose an immune threat. One therapeutic an-
gle for the treatment of DMD is to identify small molecules that 
up-regulate utrophin protein expression. Our fi  ndings now es-
tablish that SSPN regulates utrophin protein levels and localiza-
tion within the myofi  ber. 
  The results in this study were unexpected because, for 
nearly 10 yr, the precise function of SSPN has remained elusive. 
Our experiments show that SSPN is a critical mediator of protein 
In addition, expression of SSPN in   mdx   mice was associated with 
a reduction in the number of smaller, atrophic muscle fi  bers 
(Fig. S1, available at http://www.jcb.org/cgi/content/full/jcb
.200808027/DC1). This reduction of small, newly regenerating 
fi  bers provides an additional measure of muscle pathology and 
is similar to the results reported for microdystrophin (  Gregorevic 
et al., 2006  ). 
  Loss of the DGC from the sarcolemma causes membrane 
instability, which is the primary defect of dystrophin-defi  cient 
muscular dystrophy (  Weller et al., 1990  ;   Menke and Jockusch, 
1991  ;   Petrof et al., 1993  ;   Straub et al., 1997  ). Unrepaired tears in 
the sarcolemma allow proteins that are normally restricted to the 
blood serum to freely diffuse across the sarcolemma and accu-
mulate in the sarcoplasm. To further test the functionality of the 
UGC in SSPN-Tg:  mdx   mice, we performed a tracer assay with 
  Figure 4.       SSPN improves muscle degeneration and sarcolemmal stability.   
(A) Central nucleation (percent of total ﬁ  bers) was quantiﬁ  ed for quadriceps 
isolated from   mdx   and SSPN-Tg:  mdx   (  n   = 4). SSPN-Tg:  mdx   mice display 
a threefold reduction in central nuclei compared with   mdx   age-matched 
controls. Each value represents mean   ±   SEM (error bars) of the total quad-
riceps analyzed (*, P = 6.0   ×   10 
    4  ). (B) To examine inﬁ  ltration of blood 
serum proteins into damaged muscle ﬁ  bers,   mdx   and SSPN-Tg:  mdx   mice 
were intraperitoneally injected with Evans blue dye, a marker for mem-
brane instability.   mdx   quadriceps displays many Evans blue dye  –  positive 
ﬁ  bers (visualized by red ﬂ  uorescence), which is a marker for membrane 
damage. Evans blue dye was not detected in muscle from SSPN-Tg:  mdx   
mice, demonstrating that SSPN expression restored membrane stability in 
dystrophin-deﬁ  cient muscle. Bar, 20   μ  m.     425 SARCOSPAN REDUCES DYSTROPHIC PATHOLOGY   • Peter et al. 
before beginning the staining procedure. Sections were incubated with he-
matoxylin for 3 min, washed with water for 1 min, incubated with eosin for 
3 min, and dehydrated in solutions of 70, 80, 90, and 100% ethanol. 
Sections were then incubated in xylene for a total of 6 min. Sections were 
left at RT brieﬂ  y to dry before mounting with Permount. All supplies for the 
H  &  E staining were purchased from Thermo Fisher Scientiﬁ  c. 
  To measure the ﬁ  ber area and count centrally nucleated ﬁ  bers, digi-
tized images were captured under identical conditions using an Axioplan 2 
ﬂ  uorescent microscope and Axiovision 3.0 software (Carl Zeiss, Inc.). 
The percentage of centrally nucleated ﬁ  bers and ﬁ  ber areas were assessed 
for four SSPN-Tg:  mdx   and four non-Tg:  mdx   mice. Data for central nucle-
ation are represented as a percentage of the total ﬁ  bers counted. Fiber ar-
eas and central nucleation percentages were averaged, and the standard 
error is represented. Sigma Plot software (Systat Software, Inc.) was used 
to perform statistical analysis. Entire quadriceps images were attained 
using a microscope (AxioImager M1, Carl Zeiss, Inc.) and Axiovision Rel. 4.5 
software (Carl Zeiss, Inc.). 
  Protein preparation 
  Skeletal muscle was snap frozen in liquid nitrogen and ground to a ﬁ  ne 
powder with a mortar and pestle. Pulverized muscle was added to ice-cold 
modiﬁ  ed radioimmunoprecipitation assay lysis buffer with phosphatase 
inhibitors (1% Nonidet P-40, 0.5% sodium deoxycholate, 0.1% SDS, 1 mM 
EDTA, 5 mM   N  -ethylmaleimide, 50 mM sodium ﬂ  uoride, 2 mM     -glycero-
phosphate, 1 mM sodium orthovanadate, 100 nM okadaic acid, 5 nM 
microcystin-  L  -arginine, and 20 mM Tris-HCl, pH 7.6) and protease inhibitors 
(0.6   μ  g/ml pepstatin A, 0.5   μ  g/ml aprotinin, 0.5   μ  g/ml leupeptin, 0.75 mM 
benzamidine, and 0.1 mM PMSF). Homogenates were rocked at 4  °  C for 
1 h. After clariﬁ  cation by centrifugation at 15,000   g   for 15 min, tissue 
lysates were stored at     80  °  C. 
  Immunoblot analysis 
  Protein concentrations were determined using the DC Protein Assay (Bio-
Rad Laboratories). Equal concentrations (60   μ  g) of protein samples were 
resolved by 5, 10, or 15% SDS-PAGE and transferred to nitrocellulose 
membranes (Millipore) for subsequent immunoblotting. Primary antibodies 
against dystrophin (MANDYS1, 1:10), utrophin (NCL-DRP2, 1:5),     -DG 
(IIH6C-4, 1:1,000),     -DG (MANDAG2, 1:250),     -SG (VP-A105, 1:100), 
    -SG (VP-B206, 1:100),     -SG (VP-G803, 1:100; Vector Laboratories), and 
hSSPN (afﬁ  nity-puriﬁ  ed rabbit 15, 1:500) were incubated at RT while shak-
ing for 18 h. Horseradish peroxidase  –  conjugated anti  –  rabbit IgG (GE 
Healthcare) and anti  –  mouse IgG (GE Healthcare) and IgM (Upstate Signal-
ing) secondary antibodies were used at 1:3,000 dilutions. All immunoblots 
were developed using enhanced chemiluminescence (SuperSignal West 
Pico Chemiluminescent Substrate; Thermo Fisher Scientiﬁ  c). 
  Puriﬁ  cation of the UGC 
  0.1 g/ml of SSPN-Tg:  mdx   total skeletal muscle protein samples was pre-
pared using standard DGC solubilization buffer (50 mM Tris-HCl, pH 
7.8, 500 mM NaCl, and 1% digitonin) and protease inhibitors (0.6 
  μ  g/ml pepstatin A, 0.5   μ  g/ml aprotinin, 0.5   μ  g/ml leupeptin, 0.75 mM 
benzamidine, 0.1 mM PMSF, 5   μ  M calpain I, and 5   μ  M calpeptin;   Crosbie 
et al., 1998  ). Homogenates were rocked at 4  °  C for 1 h. After clariﬁ  ca-
tion by centrifugation at 15,000   g   for 20 min, lysate was then rotated 
overnight at 4  °  C with 1 ml agarose-bound succinylated WGA (AL-1023; 
Vector Laboratories). Succinylated WGA agarose was washed by rotat-
ing samples at 4  °  C four times for 10 min with wash buffer (50 mM Tris-
HCl, pH 7.8, 500 mM NaCl, and 0.1% digitonin), including protease 
inhibitors (0.75 mM benzamidine, 0.1 mM PMSF, 5   μ  M calpain I, and 
5   μ  M calpeptin) to remove unbound proteins. Bound proteins were eluted 
with 0.3 M   N  -acetylglucosamine (Sigma-Aldrich) and concentrated using 
columns (Centricon Ultracel; Millipore) by centrifugation at 4,000   g   for 
20 min. Protein concentration was determined with the DC Protein Assay. 
A 200-  μ  g sample was layered on top of a 5  –  30% sucrose gradient pre-
pared by adding 6 ml of a 5% sucrose solution into an open top centri-
fuge tube (Polyclear; Seton) using a 14-gauge Hamilton syringe and 
underlaying with an equal volume of a 30% sucrose solution. Gradients 
were mixed using the Gradient IP station (Biocomp). Sucrose gradients 
were centrifuged at 35,000   g   in an ultracentrifuge (Optima L-90K; Beck-
man Coulter) for 12 h at 4  °  C using an SW41 rotor (Beckman Coulter). 
12 1-ml fractions were collected, and 80   μ  l of each fraction was resolved 
by 8% isocratic or 4  –  20% gradient SDS-PAGE and transferred to nitro-
cellulose membranes for subsequent immunoblotting. All immunoblotting 
was performed as described in the previous section with the exception of 
utrophin (MANCHO3, 1:200; Developmental Studies Hybridoma Bank), 
which was incubated at 4  °  C. 
interactions within UGC and raise the possibility that SSPN con-
tributes to the assembly and targeting of the UGC. This is im-
pressive considering that SSPN, the smallest member of the 
complex, must orchestrate proper structural arrangement of over 
seven large peripheral and integral membrane proteins. These 
properties are unique to SSPN and suggest that gene therapeutic 
strategies targeting SSPN expression may be benefi  cial for the 
treatment of DMD. 
  Materials and methods 
  Generation of SSPN-Tg:  mdx   mice 
  Transgenic constructs were engineered with the human skeletal actin pro-
moter and the VP1 intron upstream of hSSPN as described previously 
(  Crawford et al., 2000  ;   Spencer et al., 2002  ;   Peter et al., 2007  ). SSPN 
transgenic males, line 29.1, were bred with   mdx   females (The Jackson 
Laboratory) to produce male SSPN-Tg:  mdx   mice. Female SSPN-Tg (wild 
type) and non-Tg (wild type) mice as well as male non-Tg:  mdx   littermates 
were used as controls. Mice were analyzed at 6 wk of age. Transgenic 
mice used for this study expressed an approximately twofold increase in 
SSPN protein expression in skeletal muscle compared with non-Tg (wild 
type) mice (  Peter et al., 2007  ). All mice were maintained in the Life Sci-
ences Vivarium, and all procedures were carried out in accordance with 
guidelines set by the University of California, Los Angeles Institutional 
Animal Care and Use Committee. 
  Immunoﬂ  uorescence 
  Quadriceps from female SSPN-Tg (wild type), female non-Tg (wild type), 
male non-Tg:  mdx  , and SSPN-Tg:  mdx   littermates were dissected from 6-wk-
old mice. Muscles were covered in 10.2% polyvinyl alcohol/4.3% poly-
ethylene glycol and rapidly frozen in liquid nitrogen  –  cooled isopentane. 
Mounted muscle was stored at     80  °  C until analyzed. 8-  μ  m transverse 
sections were prepared using a cryostat (CM 3050S; Leica) and stored on 
positively charged glass slides (VWR). Sections were stored at     80  °  C for 
future analysis. Sections were acclimated to RT for 15 min and blocked 
using 3% BSA diluted in PBS for 1 h at RT. Sections were then incubated 
at 4  °  C for 18 h with antibodies to the following proteins (antibody dilu-
tions are indicated): dystrophin (MANDYS1, 1:10; Developmental Stud-
ies Hybridoma Bank), utrophin (NCL-DRP2, 1:5; Vector Laboratories), 
    -DG (IIH6C-4, 1:100; Upstate Signaling),     -DG (MANDAG2, 1:50; De-
velopmental Studies Hybridoma Bank),     -SG (VP-A105, 1:100; Vector 
Laboratories),     -SG (VP-B206, 1:50; Vector Laboratories), hSSPN (afﬁ  nity-
puriﬁ  ed rabbit 15, 1:25), and mouse SSPN (afﬁ  nity-puriﬁ  ed rabbit 18, 
1:25). Polyclonal antibodies to endogenous (mouse) and exogenous (hu-
man) SSPN have been described previously (  Peter et al., 2007  ). Primary 
antibodies were detected by FITC-conjugated anti  –  rabbit and anti  –  mouse 
(Jackson ImmunoResearch Laboratories and Millipore) secondary anti-
bodies diluted at 1:500. Secondary antibodies were incubated for 1 h at RT. 
To preserve the ﬂ  uorescence signal, sections were mounted in Vectashield 
(Vector Laboratories). To determine the level of nonspeciﬁ  c staining, sec-
ondary antibodies alone were incubated with sections. Mounted sections 
were visualized using a ﬂ  uorescent microscope (Axioplan 2; Carl Zeiss, 
Inc.) equipped with a Plan Neoﬂ  uar 40  ×   NA 1.3 oil differential interfer-
ence contrast objective, and images were captured using Axiovision 3.0 
software (Carl Zeiss, Inc.). 
  Evans blue tracer assay 
  To establish sarcolemmal integrity, mice were injected with 50   μ  l of Evans 
blue dye (10 mg/ml in 10 mM of sterile phosphate buffer and 150 mM 
NaCl, pH 7.4) per 10 g of body weight as described previously (  Straub 
et al., 1997  ). Peritoneal cavity injection was performed on 6-wk-old SSPN-
Tg:  mdx   and non-Tg:  mdx   littermates. 24 h after injection, quadricepses 
were excised and mounted as described in the Immunoﬂ  uorescence sec-
tion. 8-  μ  m transverse sections were brieﬂ   y ﬁ   xed in ice-cold acetone, 
washed in PBS (10 mM phosphate buffer and 150 mM NaCl, pH 7.4), 
and mounted with Vectashield. Evans blue  –  positive myoﬁ   bers were ob-
served using an Axioplan 2 ﬂ  uorescent microscope and a Plan Neoﬂ  uar 
40  ×   NA 1.3 oil differential interference contrast objective. 
  Histology 
  H  &  E staining was used for visualization of ﬁ  brosis, central nuclei, and ﬁ  ber 
diameter. 8-  μ  m transverse quadriceps sections were left at RT for 15 min JCB • VOLUME 183 • NUMBER 3 • 2008  426
  Functional correction of adult   mdx   mouse muscle using gutted adenoviral 
vectors expressing full-length dystrophin.       Proc. Natl. Acad. Sci. USA   .  
 99 : 12979  –  12984 .    
   Durbeej ,   M. ,  and   K.P.    Campbell .   2002 .   Muscular  dystrophies  involving  the  dys-
trophin-glycoprotein complex: an overview of current mouse models.   
  Curr. Opin. Genet. Dev.     12 : 349  –  361 .    
   Ervasti ,   J.M. ,  and   K.P.    Campbell  .   1991  .   Membrane organization of the dystro-
phin-glycoprotein complex.       Cell   .    66 : 1121  –  1131 .    
   Ervasti ,   J.M. ,  and   K.P.    Campbell .   1993 .   A  role  for  the  dystrophin-glycoprotein 
complex as a transmembrane linker between laminin and actin.       J. Cell 
Biol.     122 : 809  –  823 .    
   Ervasti ,   J.M. ,   K.    Ohlendieck ,   S.D.    Kahl ,   M.G.    Gaver ,  and   K.P.    Campbell .   1990 . 
 Defi  ciency of a glycoprotein component of the dystrophin complex in 
dystrophic muscle.       Nature   .    345 : 315  –  319 .    
   Ervasti ,   J.M. ,   S.D.    Kahl ,  and   K.P.    Campbell .   1991 .   Purifi  cation of dystrophin 
from skeletal muscle.       J. Biol. Chem.     266 : 9161  –  9165 .  
   Grady ,   R.M. ,   H.    Zhou ,   J.M.    Cunningham ,   M.D.    Henry ,   K.P.    Campbell  , and   J.R.  
  Sanes  .   2000  .   Maturation and maintenance of the neuromuscular synapse: 
genetic evidence for roles of the dystrophin  – glycoprotein  complex.  
  Neuron   .    25 : 279  –  293 .    
   Gregorevic ,   P. ,   J.M.    Allen ,   E.    Minami ,   M.J.    Blankinship ,   M.    Haraguchi ,   L.  
 Meuse ,   E.    Finn ,   M.E.    Adams ,   S.C.    Froehner ,   C.E.    Murry ,  and   J.S.  
 Chamberlain .   2006 .   rAAV6-microdystrophin  preserves  muscle  func-
tion and extends lifespan in severely dystrophic mice.       Nat. Med.   
 12 : 787  –  789 .    
   Hemler ,   M.E.     2003  .   Tetraspanin proteins mediate cellular penetration, invasion, 
and fusion events and defi  ne a novel type of membrane microdomain.   
  Annu. Rev. Cell Dev. Biol.     19 : 397  –  422 .    
   Holt ,   K.H. ,  and   K.P.     Campbell  .   1998  .   Assembly of the sarcoglycan complex. 
Insights for muscular dystrophy.       J. Biol. Chem.     273 : 34667  –  34670 .    
   Jasmin ,   B.J. ,   H.    Alameddine ,   J.A.    Lunde ,   F.    Stetzkowski-Marden ,   H.    Collin , 
 J.M.    Tinsley ,   K.E.    Davies ,   F.M.    Tome ,   D.J.    Parry , and   J.    Cartaud .   1995 . 
  Expression of utrophin and its mRNA in denervated   mdx   mouse muscle.   
  FEBS Lett.     374 : 393  –  398 .    
   Judge ,   L.M. ,   M.    Haraguchiln ,  and   J.S.    Chamberlain .   2006 .   Dissecting  the  signaling 
and mechanical functions of the dystrophin-glycoprotein complex.   
  J. Cell Sci.     119 : 1537  –  1546 .    
   Levy ,   S.  , and   T.     Shoham  .   2005  .   The tetraspanin web modulates immune-signal-
ling  complexes.     Nat. Rev. Immunol.     5 : 136  –  148 .    
   Matsumura ,   K. ,   J.M.    Ervasti ,   K.    Ohlendieck ,   S.D.    Kahl ,  and   K.P.     Campbell  . 
  1992  .   Association of dystrophin-related protein with dystrophin-associated 
proteins in   mdx   mouse muscle.       Nature   .    360 : 588  –  591 .    
   Menke ,   A. ,  and   H.    Jockusch .   1991 .   Decreased  osmotic  stability  of  dystrophin-
less muscle cells from the mdx mouse.       Nature   .    349 : 69  –  71 .    
   Michele ,   D.E. ,  and   K.P.    Campbell .   2003 .   Dystrophin-glycoprotein  complex: 
post-translational processing and dystroglycan function.       J. Biol. Chem.   
 278 : 15457  –  15460 .    
   Miller ,   G. ,   E.L.    Wang ,   K.L.    Nassar ,   A.K.    Peter ,  and   R.H.    Crosbie .   2007 . 
  Structural and functional analysis of the sarcoglycan-sarcospan sub-
complex.     Exp. Cell Res.       313  :  639   –   651 .    
   Odom ,   G.L. ,   P.    Gregorevic ,  and   J.S.    Chamberlain .   2007 .   Viral-mediated  gene 
therapy for the muscular dystrophies: successes, limitations, and recent 
advances.     Biochim. Biophys. Acta   .    1772 : 243  –  262 .  
   Ohlendieck ,   K. ,  and   K.P.    Campbell .   1991 .   Dystrophin-associated  proteins  are 
greatly reduced in skeletal muscle from mdx mice.       J. Cell Biol.     115 :
 1685  –  1694 .    
   Peter ,   A.K. ,  and   R.H.    Crosbie .   2006 .   Hypertrophic  response  of  Duchenne  and 
limb-girdle muscular dystrophies is associated with activation of Akt 
pathway.     Exp. Cell Res.     312 : 2580  –  2591 .    
   Peter ,  A.K. ,   G.    Miller ,  and   R.H.    Crosbie .   2007 .   Disrupted  mechanical  stability  of 
the dystrophin-glycoprotein complex causes severe muscular dystrophy 
in sarcospan transgenic mice.       J. Cell Sci.     120  :  996   –   1008 .    
   Petrof ,   B.J. ,   J.B.    Shrager ,   H.H.    Stedman ,   A.M.    Kelly ,  and   H.L.    Sweeney .   1993 . 
  Dystrophin protects the sarcolemma from stresses developed during mus-
cle contraction.       Proc. Natl. Acad. Sci. USA   .    90 : 3710  –  3714 .    
   Spencer ,   M.J. ,   J.R.    Guyon ,   H.    Sorimachi ,   A.    Potts ,   I.    Richard ,   M.    Herasse ,   J.  
 Chamberlain ,   I.    Dalkilic ,   L.M.    Kunkel ,  and   J.S.    Beckmann .   2002 .   Stable 
expression of calpain 3 from a muscle transgene in vivo: immature mus-
cle in transgenic mice suggests a role for calpain 3 in muscle maturation.   
  Proc. Natl. Acad. Sci. USA   .    99 : 8874  –  8879 .    
   Straub ,  V. ,   J.A.    Rafael ,   J.S.    Chamberlain ,  and   K.P.    Campbell .   1997 .  Animal  mod-
els for muscular dystrophy show different patterns of sarcolemmal dis-
ruption.     J. Cell Biol.     139 : 375  –  385 .    
   Tinsley ,   J.M. ,   A.C.    Potter ,   S.R.    Phelps ,   R.    Fisher ,   J.I.    Trickett ,  and   K.E.    Davies . 
  1996  .   Amelioration of the dystrophic phenotype of   mdx   mice using a 
truncated utrophin transgene.       Nature   .    384 : 349  –  353 .    
  RNA extraction and quantitative PCR analysis 
  RNA was extracted from snap-frozen total skeletal muscle from male non-
Tg:  mdx   and SSPN-Tg:  mdx   littermates using a RiboPure kit (Ambion) as per 
the manufacturer  ’  s instructions. Puriﬁ  ed RNA was quantitated using a spec-
trophotometer (DU 640; Beckman Coulter) as described in the RiboPure in-
struction manual. Equal RNA concentrations (2.3  μ  g) were reverse transcribed 
using a high-capacity cDNA reverse transcription kit (Applied Biosystems) as 
described by the manufacturer. Reverse transcription was performed on a 
Mastercycler Gradient (Eppendorf) using the following conditions: 25  °  C for 
10 min, 37  °  C for 120 min, 85  °  C for 5 s, and held at 4  °  C. 
  Quantitative PCR analysis was performed using POWER SYBR 
green PCR master mix (Applied Biosystems). Glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH) was speciﬁ  cally  ampliﬁ   ed using GAPDH for-
ward (5    -ACTCCACTCACGGCAAATTC-3    ) and GAPDH reverse (5    -TCTC-
CATGGTGGTGAAGACA-3    ) primers, which speciﬁ  cally ampliﬁ  ed a 171-bp 
target sequence in mouse GAPDH cDNA. Utrophin cDNA was ampliﬁ  ed 
using utrophin forward (5    -GGGGAAGATGTGAGAGATTT-3    ) and utro-
phin reverse (5    -GTGTGGTGAGGAGATACGAT-3    ) primers as previously 
described (  Jasmin et al., 1995  ). These primers speciﬁ  cally  ampliﬁ  ed  a 
548-bp target of the mouse utrophin sequence. All primers were used at a 
10-  μ  M concentration. cDNA was diluted 1:10 in RNase/DNase-free 
water. 1   μ  l of diluted cDNA was added to 12   μ  l of 2  ×   PCR master mix, 11   μ  l 
RNase/DNase-free water, and 0.5   μ  l of forward and reverse primers. 
Quantitative PCR analysis was performed using a single color real-time 
PCR detection system (MyiQ iCycler; Bio-Rad Laboratories). An initial de-
naturation cycle was performed at 94  °  C for 2 min. A total of 40 cycles 
consisting of denaturation at 94  °  C for 30 s, primer annealing at 60  °  C for 
30 s, and extension at 72  °  C for 30 s were performed. A ﬁ  nal extension at 
72  °  C was performed for 10 min. Data analysis was performed using 
MyiQ Optical System software version 1.0 (Bio-Rad Laboratories). Levels 
of utrophin mRNA were normalized to GAPDH controls, and SSPN-Tg:  mdx   
samples are represented relative to   mdx   controls (100%). Statistical anal-
ysis was performed using the standard   t   test. 
  Online supplemental material 
  Fig. S1 shows a reduction of atrophic ﬁ   bers upon SSPN overexpression. 
Online supplemental material is available at http://www.jcb.org/cgi/
content/full/jcb.200808027/DC1. 
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